São Paulo • BRL BioMarin Pharmaceutical Inc. (B1MR34.SA) Follow Compare 186.90 0.00 (0.00%) At close: January 30 at 4:03:27 PM GMT-3 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for B1MR34.SA 1D 5D 0.48% 1M -8.25% 3M -6.83% 6M -20.86% YTD -8.25% 1Y -18.82% 5Y -0.51% All -0.51% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: B1MR34.SA View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Why This 1 Value Stock Could Be a Great Addition to Your Portfolio FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now? BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 Here is Why Growth Investors Should Buy BioMarin (BMRN) Now Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines Related Tickers REGN34.SA Regeneron Pharmaceuticals, Inc. 65.74 -1.81% 22UA.DU BioNTech SE 118.50 +0.42% 0A3M.IL BioNTech SE 122.95 -0.41% TECH Bio-Techne Corporation 73.55 +1.09% MRNA Moderna, Inc. 39.42 -3.95%